Covid-19: Vaccinations and Global Public Health

Debate between Lord Parkinson of Whitley Bay and Lord Purvis of Tweed

Thursday 9th September 2021 Lords Chamber

[Lord Parkinson of Whitley Bay (Con)]

My Lords, I thank the noble Lord, Lord Boateng, for tabling this debate and all the noble Lords who have taken part. It has been urgent and passionate, but focused. As the noble Lord, Lord Browne, put it, it has demonstrated the

“rich seam of knowledge, wisdom and humanity in your Lordships’ House”.

It has been almost 19 months since the first cases of Covid-19 were reported, and nine months since widespread international vaccination programmes began. Yet, as noble Lords have rightly said today, too many people remain unvaccinated, particularly in the global south.

The rapid spread of the delta variant illustrates what we have known from the very beginning, and what the noble Baroness, Lady Lawrence, and others echoed today: nobody is safe until everyone is safe. Worldwide vaccination is essential to beat the pandemic, and UK science and diplomacy have been pivotal to the progress made so far. From the outset, Her Majesty’s Government have advocated rapid and equitable access to vaccines, and we have helped to drive the global response including, as noble Lords noted, by hosting the Global Vaccine Summit and through our presidencies of the G7 and the UN Security Council. We have been a champion for global action in this important area.

We have worked closely with our partners to design, fund and implement the COVAX Facility, which is an unprecedented initiative led by the World Health Organization, Gavi, or the global vaccine alliance, and the Coalition for Epidemic Preparedness Innovations, or CEPI. COVAX has brought together 191 countries to fund, develop, manufacture and deliver Covid vaccines, particularly to the global south. Its advanced market commitment is focused on providing safe and effective vaccines to up to 92 low-income and middle-income countries. From Benin to Zambia, from Bangladesh to Timor-Leste, it is delivering vaccines across the world.

It was launched at the Global Vaccine Summit that we hosted in June last year. The UK was among its founding donors and our total commitment of £548 million is among the largest from any donor. Thanks to our leadership at the UN General Assembly and our match-funding campaign, we helped to mobilise an additional $1 billion for COVAX from other donors by the end of 2021. The noble Lord, Lord Boateng, rightly talked about resources that have been made available—our work has helped to mobilise the resources that have been made available so far. By leading this early funding drive, we gave COVAX the purchasing power it needed to secure its first deals with manufacturers, which locked in the supply of internationally approved vaccines.

The first COVAX shots—vaccines from the University of Oxford and AstraZeneca—were delivered to Cote d’Ivoire and Ghana in March this year, just four months after the first vaccination in the UK: an historically unprecedented speed. From a standing start in June last year, COVAX has now delivered more than 230 million vaccine doses to 139 countries and territories, including 87 low and middle-income countries.

Manufacturing vaccines at scale is difficult, even for experienced companies. Delays in production have slowed progress, a frustrating fact that has rightly been echoed throughout today’s debate. However, the COVAX vaccine rollout is now poised to accelerate, with new funding, supply agreements and donation commitments in place which will provide 1.8 billion vaccines to low-and middle-income countries for early 2022. This will protect millions of front-line healthcare workers and other vulnerable people.

It is right to draw attention—as the noble Lord, Lord Boateng, and others have—to the discrepancy between the number of vaccines available in the UK and elsewhere in the world. The first duty of the Government, just as it is for all Governments around the world, is to ensure that we have sufficient vaccine supply for our own domestic rollout. I am sure that noble Lords would not disagree with that. We are ensuring that we have sufficient future supply for the UK’s needs alongside meeting our G7 commitments.

Alongside this, as noble Lords have said today, making vaccines available globally not only helps address the coronavirus pandemic in developing countries and is the morally right thing to do, but it will also reduce the threat posed by vaccine-resistant variants which are emerging and could pose a threat to us all. As my noble friend Lady Sugg put it, it is in our enlightened self-interest as a force for good in the world. Through our participation in COVAX and by sharing vaccines bilaterally, the UK is therefore also championing the need for access for all countries.

At the G7 leaders’ summit in Cornwall, the UK committed to sharing 100 million Covid-19 vaccine doses within 12 months, including 30 million by the end of this year. Of these, 80% will go to COVAX to accelerate support to countries in need. My noble friend Lady Sugg and others asked how many had been delivered so far. To date, the UK has delivered over 9 million doses—ahead of our target for the end of September—of which half are helping to meet the urgent need for vaccines in countries across Africa, south-east Asia and the Caribbean. UK donations are already helping to immunise health workers and those most vulnerable to serious illness from Covid, and to protect health systems. Our 100 million doses are part of the broader G7 promise to finance and donate a billion safe and effective vaccines worldwide by June next year.

My noble friend Lady Sugg and many others asked about the taking of vaccines from COVAX for UK use. As well as being one of the largest donors to COVAX, the UK was one of the earliest. That is pertinent here, because the UK opted into procuring the Pfizer vaccine through COVAX at a time when that was the only vaccine demonstrated to be effective and approved by the UK regulator. COVAX subsequently decided, after consulting those participating, to procure only a small amount of the Pfizer vaccine because it is, as noble Lords will know, difficult for many countries deploy, given the challenge of establishing the very cold temperatures at which it needs to be stored in the delivery chain. Our early funding to COVAX gave it the purchasing power it needed to secure deals with manufacturers to supply internationally approved vaccines for low and middle-income countries.

These practical points lead to questions posed by the noble Baroness, Lady Lawrence, and others, about donating vaccines with short shelf lives. We agree that adequate shelf life is important for all vaccines supplied to all countries. We are aiming for all donated and dose-shared vaccines to have a minimum of two months of shelf life, in line with Gavi and COVAX guidance. The partner Governments are free to refuse donations if they are concerned about expiry dates. They are working to ensure the rapid rollout of shared doses to priority groups, including people who need a second dose, and to prevent wastage. The WHO EUL vaccines are approved with a six-month expiry date at present, which may be reviewed by the WHO depending on emerging stability data.

The noble Baroness also asked what we are doing to speed up vaccine access and to tackle the problem of sell-by dates. We are working through the governing boards to ensure that Gavi and World Bank funding is available for in-country delivery and that it is approved and dispersed in a timely manner. We are also supporting COVAX to become less reliant on India-based manufacturers and to diversify its portfolio to manage risk.

The noble Baroness, Lady Brinton, asked another practical question about new variants that may evade vaccine immunity. If such a variant emerges, it should be possible for manufacturers to update vaccines to protect against it, but this means scaling up vaccine manufacturing and rolling out vaccines as quickly and widely as possible. In addition, as more people get vaccinated, we expect virus circulation to decrease. This will lead to fewer mutations, but of course we must track those mutations and variants closely to detect them, and that means carrying out genomic sequencing globally and sharing data.

The noble Baroness, Lady Bennett of Manor Castle, referred to the UK’s role in the development of the AstraZeneca vaccine. So much of what we have been debating today would not have been possible without the extraordinary work of our scientists. The UK’s scientific excellence and co-operation has enhanced collective knowledge about the virus and led to pivotal breakthroughs. The Government’s role in supporting AstraZeneca is well known and we are proud of the helping hand that we gave. The advance there has become an extraordinary gift to global vaccination efforts. More than 1 billion doses have already been delivered at cost, with no profit, with around two-thirds of them going to lower-income and middle-income countries. That has saved countless lives across the globe.

We also supported wider international collaboration to develop vaccines. In March last year the Prime Minister announced £250 million of funding for CEPI to accelerate vaccine development against global threats including Covid-19. CEPI has supported 11 vaccine candidates, including the approved Moderna vaccine, as well as Novavax, which has showed positive results in clinical trials. The UK will host a replenishment conference to raise funds for CEPI’s crucial work on vaccine development in March next year, helping it to realise the aim of making vaccines against new health threats, including new Covid variants, in just 100 days.

In addition to our support for vaccines, the UK is a world leader in viral genomic sequencing, which will be important for the reasons I outlined in response to the question from the noble Baroness, Lady Brinton. This has proved crucial in identifying the emergence of new variants and will be essential to ensuring that the vaccines remain effective. Public Health England is already working with seven countries and the Africa Centres for Disease Control to build their capacity in genomic sequencing.

A number of noble Lords raised the issue of manufacturing. The rollout of vaccines has raised important questions about TRIPS, the agreement on trade-related aspects of intellectual property rights, which the noble Baroness, Lady Chakrabarti, and others focused on in particular. We have engaged in discussions on intellectual property and a possible TRIPS waiver at the WTO and we will continue to engage constructively with the US and other WTO members, as the noble Lord, Lord Boateng, and others urged. We have not yet, however, seen conclusive evidence indicating that the removal of intellectual property protections would lead to the scaling up of production or the improvement of the supply of Covid-19 products, including vaccines. At this point we remain unconvinced on how beneficial a waiver would be.

As a practical point, any negotiations at the WTO on a waiver would need unanimous support, which could take a long time. While we will continue to engage in IP discussions and review the merits of any proposals submitted to the TRIPS council, we must also continue to push ahead with pragmatic action now, including voluntary licensing and technology transfer agreements for vaccines, support for COVAX, as I outlined, and solutions to production bottlenecks and supply chain issues. The UK is also co-sponsoring the Ottawa group’s trade and health initiative. This aims to increase co-operation among WTO members, keep medical supply chains open and lower trade barriers, getting vital supplies, including vaccines, to those who need them most.

The voluntary licensing approach taken by the team at Oxford and AstraZeneca has had our full support, as has their collaboration with the Serum Institute of India to scale up manufacturing for global supply. We welcome the work of the new Partnerships for African Vaccine Manufacturing, which is developing its road map to manufacture vaccines in Africa and engaging to identify opportunities for partnerships. We have provided technical support to Biovac, a vaccine company in South Africa, to develop an investment case, which helped secure financing to produce Covid vaccines there. We are giving similar support to the Institut Pasteur in Dakar, to companies in Senegal and to the Government of Morocco.

Noble Lords also focused on questions of distribution, and we recognise that distribution, particularly in hard-to-reach locations, is a critical challenge in many countries. Investment in delivery is vital in getting jabs into people’s arms. Multilateral development banks are playing a central role in funding health systems to deliver vaccines, treatment and testing while maintaining other essential services, and the UK has led engagement with multilateral banks to strengthen co-ordination with COVAX and speed up the processes for applications and release of funds. The FCDO is also working with UNICEF and other humanitarian partners to ensure that planning and finance are in place to address the challenges of distribution in difficult environments.

It is extremely difficult for charities and healthcare workers safely to provide jabs to people living in conflict zones, so the UK used its presidency of the UN Security Council in February to secure unanimous support for a resolution calling for ceasefires in conflict zones to enable vaccine delivery. We continue to work with our international partners to monitor and support the implementation of that important resolution.

[Lord Purvis of Tweed (LD)]

I am not sure whether the Minister will be coming back to the UK and COVAX. He has been asked very specific questions: to confirm whether in fact the UK drew down 539,000 doses in June and whether we have in fact negotiated options for a further 27 million doses. He was asked whether the Government will confirm that they will not draw down those 27 million doses.

[Lord Parkinson of Whitley Bay (Con)]

I cannot confirm that number, but I outlined that we drew down some of the Pfizer vaccine for the practical reasons that I gave—the difficulty of distributing and using those doses—with the agreement of those taking part. I fear I cannot give the commitment that the noble Lord asked for today, but I will certainly take his questions and those from other noble Lords back to the Vaccine Taskforce and will ensure that all noble Lords who have taken part in the debate get the answer to that.

The goal to which we and our G7 partners have committed—to vaccinate the world in 2022—is a monumental one. Much has been achieved already but, as today’s debate has powerfully underlined, we know that there is much more to do. The points noble Lords have raised today, particularly on manufacturing and distribution, are significant issues, which the UK is working with our partners to tackle.

International collaboration remains the key to ending this global pandemic, and we will continue to work with our international partners through the autumn, including at UNGA, the G7 and the G20, to support the G7 commitment to vaccinate the world in 2022. The international community must work together to get vaccines to those who need them around the world, and Her Majesty’s Government are determined to do all we can to ensure that that happens.

International Development (Official Development Assistance Target) Act 2015

Debate between Lord Parkinson of Whitley Bay and Lord Purvis of Tweed

Wednesday 25th November 2020 Lords Chamber

[Lord Parkinson of Whitley Bay (Con)]

The noble Lord is right to point to the current circumstances of the pandemic as a forcible reminder of the importance of assisting people around the world: these are global problems. That is why the United Kingdom is one of the largest donors to the international Covid-19 response. We have already committed up to £1.3 billion to combat the pandemic and to reinforce the global effort to find and equitably distribute a vaccine.

[Lord Purvis of Tweed (LD)]

My Lords, the Act in which I had a role—the Minister kindly referred to it—was as a result of consensus. Now, as the Chancellor has finished his Statement and it has been released, the Minister no longer needs to speculate; he can read from his brief what the reality is to the House. That reality could well be the biggest reduction in UK overseas assistance in a generation. Can the Minister look me—the sponsor of the International Development (Official Development Assistance Target) Act in this House—in the eye? There is no provision in this Act for a Secretary of State to proactively and deliberately miss the 0.7% target; it is the law and a duty. Will the Government uphold the law, and can the Minister confirm to me, personally and directly, that Secretaries of State will continue to uphold their legal duty under that Act?